Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.61
- Piotroski Score 8.00
- Grade Buy
- Symbol (HALO)
- Company Halozyme Therapeutics, Inc.
- Price $57.31
- Changes Percentage (-1.99%)
- Change -$1.16
- Day Low $57.09
- Day High $58.00
- Year High $65.53
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/18/2025
- Fiscal Year End N/A
- Average Stock Price Target $58.00
- High Stock Price Target $65.00
- Low Stock Price Target $44.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.41
- Trailing P/E Ratio 21.1
- Forward P/E Ratio 21.1
- P/E Growth 21.1
- Net Income $281.59 M
Income Statement
Quarterly
Annual
Latest News of HALO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SpaceX Partner Rockets On Halo Development Deal
AST SpaceMobile signed a contract with the Space Development Agency (SDA) for satellite projects. The company aims to offer global connectivity at high speeds. ASTS stock surged following the announce...
By Investor's Business Daily | 1 week ago -
Nexalin trials Halo neurostimulation device in traumatic brain injury
Nexalin Technology and UC San Diego collaborate for a clinical trial on Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury. The study aims to assess brain activity and symptom ...
By Yahoo! Finance | 1 week ago -
VQ's Halo Bluetooth Speaker Works As A Lantern And Power Bank
British brand VQ has introduced the Halo Bluetooth speaker, perfect for winter with its rechargeable power bank, 360-degree sound, and mood lighting. Ideal for indoor or outdoor use, it offers True Wi...
By Forbes | 2 weeks ago
